Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idelalisib + Ofatumumab in Previously Untreated CLL and SLL
NCT02135133Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jun 2014
- Primary completion
- Oct 2020
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of idelalisib, ofatumumab in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Dana-Farber Cancer Institute. Started Jun 2014; status: completed.
02
Drugs
idelalisibofatumumab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT02135133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02135133.